Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ: CSTL )

26.04 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Castle’s Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test
From Castle Biosciences Inc.
Via Business Wire
Beyond The Numbers: 7 Analysts Discuss Castle Biosciences Stock
Via Benzinga
The Analyst Landscape: 4 Takes On Castle Biosciences
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma
From Castle Biosciences Inc.
Via Business Wire
Guardant Health Stock Sees RS Rating Jump To 83
On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. 
Via Investor's Business Daily
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
From Castle Biosciences Inc.
Via Business Wire
Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Reports Third Quarter 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
From Castle Biosciences Inc.
Via Business Wire
Momentum Has Narrowed Again, Significantly
It is more of a stock pickers market than usual as momentum factors are currently exaggerated. 
Via Talk Markets
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
From Castle Biosciences Inc.
Via Business Wire
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
From Castle Biosciences Inc.
Via Business Wire
New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
From Castle Biosciences Inc.
Via Business Wire
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
From Castle Biosciences Inc.
Via Business Wire
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
From Castle Biosciences Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.